我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

培哚普利对心衰患者心律失常的治疗作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
1999年第1期
页码:
11-14
栏目:
论著
出版日期:
1999-01-01

文章信息/Info

Title:
Therapeutic effects of pendopril on arrythmia in patients with congestive heart failure
作者:
宋耀明　何作云　孟素荣
第三军医大学新桥医院心内科 重庆 400037
Author(s):
Song Yaoming ;  He Zuoyun; Meng Surong
Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037
关键词:
心力衰竭　抑制剂;  血管紧张素转换酶　心源性猝死
Keywords:
heart failure　inhibitor angiotensin converting enzyme　cardiogenic sudden death
分类号:
-
DOI:
-
文献标识码:
-
摘要:
在血管紧张素转换酶抑制剂(ACEI)培哚普利使用后,观察心功能及心律失常的变化,以明确ACEI对充血性心力衰竭(CHF) 患者心律失常的治疗作用。CHF患者352例随机分为培哚普利组(T组)和对照组(C组),T组在C组基础上加用培哚普利2 mg/d～4 mg/d,分别在用药前及用药后4个月、12个月、24个月进行24 hHolter、心脏二维超声检查测定心功能及左室形态变化。结果T组4个月、12个月、24个月后室早、成对室早、室速及新发室速发生率较C 组明显降低, T组心源性猝死发生率的降低平行于室速发生率的降低。T组4个月、12个月、24个月后左室射血分数、左室周边缩短率、心指数较C组明显好转, 而左室心肌重量、左室后壁厚度、左室舒张期末径较C组亦改善明显。可见ACEI可通过改善CHF患者心功能及左室重构, 降低室性心律失常发生率及降低心源性猝死发生率。提示ACEI是降低CHF患者心源性猝死的有效药物。
Abstract:
Objective:The changes in cardiac function and ventricular arrythmia were observed in patients with congestive heart failure (CHF) to investigate the therapeutic effects of pendopril,a angiotensin converting enzyme inhibitor, on arrythmia.Methods:Three hundred and fifty-two patients with CHF were randomized into the pendopril-treated group(TG)and the control group(CG).The patients in TG were treated with pendopril at a dosage of 2mg/d～4mg/d. The 24 h Holter was determined and cardiac function and changes in left ventricular morphology were investigated with ultrasonography before and at the 4th, 12th and 24th month after the treatment.Results: The occurring rates of ventricular premature beat, couple ventricular premature beat,ventricular tachycardia and new-formed ventricular tachycardia were significantly lower in TG than in CG at the 4th, 12th and 24th month after the treatment. The decrement of the occurring rate of cardiogenic sudden death pralleled the decrement of the occurring rate of ventricular tachycardia. At the 4th, 12th and 24th month after the treatment, EF mVcf, CI,LVM , PWT and Dd were markedly improved in TG as compared with CG. Conclusion: Pendopril can decrease the occurring rate of ventricular arrythmia and the rate of cardiogenic sudden death through improving cardiac function and left ventricular remodeling,which suggests that pendopril is a effective agent to decrease the rate of cardiogenic sudden death in patients with CHF.

参考文献/References

［1］Ho KKL ,Anderson KM , Kannel WB, et al. Survival after the onset of congestive heart failure in framingham heart. Circulation,1993; 88 (1) : 107.

［2］Gomes JA ,Mehta D,Winters SL , et al. Predictors of long-term survival in patients with malignant ventricular arrhythmias. Am Cardiol, 1997; 79 (8) : 1054.

［3］Cohn JN , Johnson G, Ziesche S, et al. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic heart failure. N Eng1 J Med , 1991; 325: 303.

［4］Micheli DA ,Medrano GA , Iturralde P, et al. Effects of verapamil in ventricular tachycardias. An experimental and clinical study.Acta Cardiol, 1997; 52 (1) : 1.

［5］Fletcher RD, Guillermo BC, Johnson C, et al. Enalapril decreases prevalence of tachycardia in patients with chronic congestive heart failure. Circulation, 1993; 87 (supp l) : 49.

[6]Hattori Y, Atsushi S, Hiroaki F, et al. Effects of cilazapril on ventricular arrhythmia with congestive heart failure. Clin Ther,1997 May-Jun; 19 (3) : 481.

[7]Racker HF, Koppers D, Lemke P, et al. Fosinoprilate prolongs the action potential: reduction of ik and enhancement of the Ltype calcium current in guinea pig ventricular myocytes. Cardiovasc Res, 1994; 28: 201.

[8]Linz W , Schoelkens BA , Han YF, et al. Beneficial effects of the converting enzyme inhibitor ramipril in ischemic hearts. J Hypertens, 1986; 8 (supp110) : S91.

[9]Swedberg K, Eneroth K, jekshus J , et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. The CONSENSUS Trial study Group. Circulation, 1990; 82 (5) : 1730.

[10]Lindpaintner K,Wilhelm MJ. Tissue renin-angiotensin systems:focus on the heart. J Hypertens , 1987; 5 (supp12) : S33.

[11]Kunupuli SP, Kumar A. Molecular cloning of human angiotensinogen cDNA and evidence for the presence of its mRNA in the rat heart. Circ Res, 1987; 60 (5) : 786.

备注/Memo

备注/Memo:
(收稿1998-11-20)
更新日期/Last Update: 1999-01-01